


What is claimed is:


1. A compound of formula I



I

- 5 or a pharmaceutically acceptable salt thereof wherein:

A is structure i, ii, iii, or iv



X^1 and Y^1 together form the group $-C(=O)N(R^5)-$ wherein X^1 is either $C(=O)$ (and Y^1 is NR^5) or X^1 is NR^5 (and Y^1 is $C(=O)$).

- 10 Z^1 is

- (a) $NHC(=O)R^1$,
 (b) $NHC(=S)R^1$,
 (c) $NH-het^1$,
 (d) $O-het^1$,
 (e) $S-het^1$, or
 (f) het^2 ,

15

R^1 is

- (a) NH_2 ,
 (b) $NHC_{1-4}alkyl$,
 (c) $C_{1-4}alkyl$,
 (d) $C_{2-4}alkenyl$,
 (e) $-CH_2C(=O)C_{1-4}alkyl$,
 (f) $OC_{1-4}alkyl$,
 (g) $SC_{1-4}alkyl$, or
 (h) $C_{3-6}cycloalkyl$,

20

25

Each X, Y, and Z is independently selected from

- (e) H,
- (f) Cl,
- (g) F, or
- (h) CH₃

5

R⁴ is

- (a) H,
- (b) C₁₋₄alkyl,
- (c) OC₁₋₄alkyl,
- (d) SC₁₋₄alkyl, or
- (e) NHC₁₋₄alkyl;

10

R⁵ is

- (a) H,
- (b) C₁₋₄alkyl, or
- (c) -(CH₂)_n-W₁-(CH₂)_n-Z³;

15


W₁ is

- (a) -CH₂-,
- (b) -CH=CH-,
- (c) -C≡C-, or

20



Z³ is



25

W₂ is

- (a) -O-,
- (b) -N(R₂₅)-, or
- (c) -C(=O)-N(R₂₅)-, wherein either the carbon or the nitrogen atom of the

amide may be bound to a carbon atom of the phenyl ring of Z³;

30

R₂₂ is (CH₂)_tNR₂₃R₂₄, H, halo, C₁₋₄alkyl, -CN, -OH, -O-C₁₋₄alkyl, -S(O)_uC₁₋₄alkyl, and -C(=O)NH₂

R₂₃ is H or C₁₋₄ alkyl;

R₂₄ is H, C₁₋₄ alkyl, -S(O)₂-C₁₋₄alkyl, -C(=O)-C₁₋₄ alkyl, -C(=NH)-NH₂,
-C(=O)-C(HR₂₆)-NR₂₇R₂₈;

R₂₅ is H or C₁₋₄ alkyl;

5 R₂₆ is H, C₁₋₄ alkyl which can be optionally substituted by -OH, -NH₂, -NH-C(=NH)-NH₂, -SH, -SCH₃, -COOH, -C(O)NH₂, and phenyl which can be optionally substituted with -OH, imidazole, indole, or R₂₆ and R₂₇ together with the carbon atom to which R₂₆ attaches and the nitrogen atom to which R₂₇ attaches form a heterocycloalkyl;

10 R₂₇ is H or C₁₋₄ alkyl;

R₂₈ is H, C₁₋₄ alkyl, -S(O)₂-C₁₋₄alkyl, -C(=O)-C₁₋₄ alkyl, -C(=NH)-NH₂,
-C(=O)-C(HR₂₆)-NR₂₇R₂₇

t is 0, 1;

u is 0, 1, 2;

15 n is 1 or 2;

het¹ is a C-linked five- (5) or six- (6) membered heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen; het¹ being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy, halogen -CN, =O, =S, and
20 being optionally substituted with C₁-C₄alkyl;

het² is a N-linked five- (5) or six- (6) membered heterocyclic ring having at least one nitrogen atom, and optionally having one oxygen or sulfur atom; het² being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy, halogen -CN, =O, =S, and being
25 optionally substituted with C₁-C₄alkyl;

heterocycloalkyl is a four (5) or seven (7) membered saturated heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen; heterocycloalkyl being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C₁-C₄alkyl, amino, C₁-C₄alkylamino, C₁-C₄alkyloxy,
30 halogen -CN, =O, =S, and being optionally substituted with C₁-C₄alkyl;

at each occurrence, alkyl, alkenyl, or cycloalkyl is optionally substituted with 1-3 halo, -OH, -OC₁₋₄alkyl, and

Aryl refers to phenyl, biphenyl, or naphthyl, optionally substituted with halo,

C₁₋₄ alkyl, OH, OC₁₋₄ alkyl, -CH₂NH₂, -CH₂NH(C₁₋₄ alkyl), and S(O)_uC₁₋₄alkyl.

2. The compound of claim 1, wherein A is formula ii.

5 3. The compound of claim 1, wherein X is F.

4. The compound of claim 3, wherein Y is F.

5. The compound of claim 1, wherein Z¹ is -NH-C(O)R₁.

10

6. The compound of claim 5, wherein R₁ is selected from C₁₋₄alkyl optionally substituted with 1-3 halo.

7. The compound of claim 6, wherein R₁ is C₁₋₄alkyl substituted with 1-2 halo.

15

8. The compound of claim 1, wherein Z¹ is -NH-C(S)R₁.

9. The compound of claim 8, wherein R₁ is selected from C₁₋₄alkyl optionally substituted with 1-3 halo.

20

10. The compound of claim 9, wherein R₁ is C₁₋₄alkyl substituted with 1-2 halo.

11. The compound of claim 1, wherein Y¹ is -C(=O)- and X¹ is -N(R₅)-.

25 12. The compound of claim 1, wherein X¹ is -C(=O)- and Y¹ is -N(R₅)-.

13. A compound selected from the group consisting of

N-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;

30 *N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanamide;

2,2-dichloro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide;

- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 5 *N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 2,2-dichloro-*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;
- 10 *N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroacetamide;
- N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;
- 15 *N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide;
- 2,2-dichloro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;
- 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- 20 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- ({(5*S*)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 25 *N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;
- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- 30 *N*-({(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

- N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;
 N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)-2,2-difluoroethanethioamide;
- 5 N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)acetamide;
 2,2-difluoro-N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)ethanethioamide;
 N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)propanamide; and
- 10 N-((5S)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide.
14. A compound selected from the group consisting of
- 15 N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide; N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;
 N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
- 20 N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)acetamide;
 N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl)methyl)propanamide;
 ((5S)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
- 25 N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
 N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;
- 30 N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide;
 N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanamide;

N-({(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;

N-({(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide; and

- 5 *N*-({(5*S*)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide.

15. A compound selected from the group consisting of

- 2,2-dichloro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 10 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- 15 2,2-dichloro-*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;
- N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;
- N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroacetamide;
- 20 2,2-dichloro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;
- 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- 25 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- 2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;
- N*-({(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide; and
- 30 2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide.

16. The compound 5-{2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}piperidin-2-one.
17. A method for the treatment of microbial infections in mammals comprising
5 administration of an effective amount of compound of claim 1 to said mammal.
18. The method of claim 17 wherein said compound of claim 1 is administered to the mammal orally, parenterally, transdermally, or topically in a pharmaceutical composition.
- 10 19. The method of claim 18 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.
20. The method of claim 18 wherein said compound is administered in an amount
15 of from about 1 to about 50 mg/kg of body weight/day.
21. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.